Entrar/Registro  
INICIO ENGLISH
 
Medicina Cutánea Ibero-Latino-Americana
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio


ENVÍO DE ARTÍCULOS






>Revistas >Medicina Cutánea Ibero-Latino-Americana >Año 2005, No. 4


Julià MM, Moreno RJA
Tratamientos tópicos de la psoriasis: actualización
Med Cutan Iber Lat Am 2005; 33 (4)

Idioma: Español
Referencias bibliográficas: 86
Paginas: 147-157
Archivo PDF: 244.19 Kb.


Texto completo




RESUMEN

Existen distintas modalidades terapéuticas que el dermatólogo debe tener en cuenta para tratar la psoriasis, incluyendo el tratamiento tópico, el sistémico y la fototerapia. De todas ellas, el tratamiento tópico representa el primer eslabón terapéutico. Gracias a los nuevos avances en el campo de la dermatología, hoy en día puede tratarse de manera más eficaz y segura esta crónica enfermedad. En este trabajo, se ha realizado una revisión sistemática de los últimos estudios en eficacia y beneficio de los distintos principios activos actualmente disponibles en el mercado para el tratamiento tópico de la psoriasis, además de revisar también la actualidad de los tratamientos más clásicos como son el alquitrán y la antralina. Así mismo, se exponen los efectos secundarios de cada uno de los principios activos y se destacan las mejores combinaciones terapéuticas que mejoran la eficacia, la tolerancia y el cumplimiento del tratamiento.


Palabras clave: psoriasis, tratamiento tópico, antralina, alquitrán, corticoides tópicos, calcipotriol, tazaroteno.


REFERENCIAS

  1. Werich EG. Dermatopharmacology of salicylic acid. Dermatologica 1975;15:114-6.

  2. Davies M, Marks R. Studies on the effect of salicylic acid on normal skin. Br J Dermatol 1976; 95:187-92.

  3. Krochman L, Wang JCT, Patel B. Topical corticosteroid compounding: effects on physiochemical stability and skin penetration rate. J Am Acad Dermatol 1989;21:979-84.

  4. Linden CH, Lovejoy FH Jr. Capítulo 391 Enfermedades producidas por tóxicos, sobredosis medicamentosas y venenos en: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL. Harrison: Principios de Medicina Interna. McGraw-Hill 14º edición, 1998.

  5. Lebwhol M. The role of salicylic acid in the treatment of psoriasis. In J Dermatol 1999; 38:16-24.

  6. Tanenbaum L, Parrish JA, Pathak MA et al. Tar phototoxicity and phototherapy for psoriasis. Arch Dermatol 1975;111:467-70.

  7. Stern RS, Armstrong RB, Anderson TF et al. Effect of continued ultraviolet B hototherapy on the duration of remission in psoriasis: a randomised study. J Am Acad Dermatol 1986;15:840-6.

  8. Schimd MH, Korting HC. Coal tar, pine tar and sulfonated shale oil preparations: comparative activity, efficacy and safety. Dermatology 1996;193:1-5.

  9. Bickers DR. The carcinogenicity and mutagenicity of therapeutic coal taraperspective. J Invest Dermatol 1981;77:173-4.

  10. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1980;1:732-5.

  11. Griffiths C, Camp R, Barker JNWN. Capítulo 35 Psoriasis en: Burns T, Breathnach S, Cox N, Griffiths C. Rook’s Textbook of Dermatology. Blackwell Publishing 7th ed, 2004.

  12. Tremblay J-F, Bissonnette R. Topical agents for the treatment of psoriasis, past, present and future. J Cutan Med Surg 2002; 6:S8-11.

  13. Schimdt KN et al: Anti-psoriatic drug anthralin activates transcription factor NFkB in murine keratinocytes. J Immunol 1996;156:4514.

  14. Ingram JT. The approach to psoriasis. Br Med J 1953 12;4836:591-4.

  15. Brun J, Juhlin L, Schalla W. Short-contact anthralin therapy of psoriasis with or without UV-irradiation and mainenance schedule to prevent relapses. Acta Derm Venereol (Stockh) 1984;64:174-1.

  16. Boer J Smeenk G. Effect of short-contact anthralin therapy on ultraviolet B irradiation of psoriasis. J Acad Am Dermatol 1986 15: 198-204.

  17. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2.

  18. Ramsay B, Lawrence CM, Bruce JM et al. The effect of thriethanolamine application on anthralina-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 1990;23:73-6.

  19. Lebwohl M, Peets E, Chen V. Limited application of mometasone fuorate on the face and intertriginous areas: analysis of safety and efficacy. Int J Dermatol 1993;32:830-1.

  20. Gollnick H, Menter A. Combination therapy with tazarotene plus topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999;140:S18-23.

  21. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:649-61. Tratamiento de la psoriasis. Parte 1. Tratamiento tópico y fototerapia. J Am Acad Dermatol 2001;45:487-98.

  22. Cambazard F. What do we know about the use of topical corticosteroids in the treatment of psoriasis? A systematic review of efficacy and safety. Symposium Satéltie Leo. XIII Congress AEDV Fiorence 2004. Med Cutan Iber Lat Am 2005;33:44-5.

  23. Hepburn D, Yohn JJ, Weston WL. Topical steroid treatment in infants, children and adolescents. Adv Dermatol 1994;9:225-54.

  24. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63-71.

  25. Bergstedt C, Gamborg-Nielsen P, Karlsson L, Stromberg L. Treatment of nummular psoriasis with clobetasol propionate stick. Dermatology 1992;184:51-3.

  26. Christophers E, Mrowietz U. Capítulo 42 Psoriasis en: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. Fitzpatrick’s Dermatology in General Medicine. McGraw-Hill 6th ed 2003.

  27. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-84.

  28. Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooney JJ, Jones ML, Samson CR. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991;183:269-74.

  29. Schafer-Korting M, Schmid MH, Kortin HC. Topical glucocorticoids with improved riskbenefit ratio: rationale of a new concept. Drug Saf 1996;14:375-85.

  30. Lebwohl MG, Tan MH, Meador SL, Singer G. Limited application of fluticasone propionate ointment, 0,005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001;44:77-82.

  31. Franz TJ, Parsell DA, Halualani RM, et al. Bethamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999;38:628-32.

  32. Chandraratna RAS. Tazarotene-first of a new generation of receptor-selective retinoids. Br J Dermatol 1996;135:18-25.

  33. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92.

  34. Gerald D. Weinstein, MD,a John Y. M. Koo, MD,b Gerald G. Krueger, MD,c Mark G. Lebwohl, MD, Nicholas J. Lowe, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48:760-7.

  35. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenail, an open, prospective study. Br J Dermatol 2003;149:207-9.

  36. Kaidbey K, Kopper SC, Sefton J, Gibson JR. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol 2001;40: 468–71.

  37. Weintein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ et al. Tazarotene cream in the treatment of psoriasis: Two multicentre double-blind, randomized, vehiclecontrolled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied on daily 12 weeks. J Am Acad Dermatology 2003;48:760-7.

  38. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2.

  39. Lebwhol M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 2000; 43:S43-6.

  40. Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002;6:95-102.

  41. Tzaneva S, Honigsmann H, Tanew A, Seeber A. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 2002;147:748-53.

  42. Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol 2003;4:197-202.

  43. Langer A, Ashton P, et al. A long-term study multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol 1996;135:385-9.

  44. Van de Kerkhof PCM. Biological activity of vitamina D analogues in the skin, with special references to antipsoriatic mechanisms. Br J Dermatol 1995;132:675.

  45. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits the differentiation, mauration, activation and survival of dendritic cells leading to impaired alloreacive T cell activation. J Immunol 2000;64:2405.

  46. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337:193-6.

  47. Piraccini BM, Tosti A, Iorizzo M, Misciali C. Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients. Br J Dermatol 2001;144:1000-5.

  48. Oranje AP et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997;36:2003.

  49. Lebwhol M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998; 39:447-50.

  50. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2.

  51. Kragballe K. How is safe the use of calcipotriol and dipropionate bethamethasone in the treatment of psoriasis? Results of a 52 weeks long study about safety. Symposium Satéltie Leo. XIII Congress AEDV Fiorence 2004. Med Cutan Iber Lat Am 2005;33:46-7.

  52. Van de Kerkhof PCM. The impact of a twocompound product containing calcipotriol and betamethasone dipropionato (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004;151:663-8.

  53. Speight EI, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994;130:79-82.

  54. Van de Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acetretin therapy in psoriasis. Br J Dermatol 1998;138:84-9.

  55. Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cycloporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1998;10:143-6.

  56. Mascaró JM. Vitamina D and psoralen plus UVA radiation. Cutis 2002;70:S13-5.

  57. Ramsay CA, Schwartz BE, Lowson D et al. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatic combination treatment. Dermatology 2000;200:17–24.

  58. Woo WK, McKenna KE. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebocontrolled clinical trial. Br J Dermatol 2003;149:146–150.

  59. Kerscher M, Volkenandt M, Plewig G, Lehmann P. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB. Lancet 1993;342:923.

  60. Juhlin L, Hogforsen E, Juhlin C. Parathyroid hormone relates protein is localized in the granular layer of normal skin and in the dermal infiltrates of mycosis fungoides but is absent in psoriatic lesions. Acta Derm Venereol (Stockh) 1992;72:81-3.

  61. Holick MF, Chimeh FN, Ray S. Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a ranomized selfcontrolled trial and open trial. Br J Dermatol 2003;149:370-6.

  62. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44: S1-12.

  63. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002;16:100-14.

  64. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos J, et al. A short-tem trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337:816-21.

  65. Choi CJ, Nghiem P, Tacrolimus ointment in the treatment of chronic cutaneous graftversus-host disease: a case series of 18 patients. Arch Dermatol 2001;137:1202-6.

  66. Rozycki T, Rogers R, Pittelkow M, McEvoy MT, el-Azhary RA, Bruce AJ, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002;46:27-34.

  67. Goldman D. Tacrolimus ointment for the treatment of steroidinduced osacea: a preliminary report. J Am Acad Dermatol 2001;44:995-8.

  68. Suga Y, Tsuboi R, Hashimoto Y, Yaguchi H, Ogawa H. A case of ichthyosis linearis circumflexa successfully treated with topical tacrolimus. J Am Acad Dermatol 2000;42: 520-2.

  69. Schuppe HC, Homey B, Assmann T, Martens R, Ruzicka T. Topical tacrolimus for pyoderma gangrenosum. Lancet 1998; 351:832.

  70. Kanekura T, Yoshii N, Terasaki K, Miyoshi H, Kanzaki T. Efficacy of topical acrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003;148: 353-6.

  71. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998;111:396-8.

  72. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-64.

  73. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-87.

  74. Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, Lebwohl M. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48:564-8.

  75. Ruzicka T, Assmann T, Lebwohl M. Potential future dermatological indications for tacrolimus ointment. Eur J Dermatol. 2003; 13:331-42.

  76. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003;17:493-503.

  77. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, Dubertret L, Bos JD. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998;134:1101-2.

  78. Erdogan M, Wright JR Jr, McAlister VC. Liposomal tacrolimus lotion as a novel topical agent for the treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol 2002;146:964–7.

  79. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI.Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141:103-7.

  80. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs 2000;9:69-77.

  81. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6.

  82. Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol (Stockh) 2003;83:351-3.

  83. Clayton TH, Harrison PV, Nicholls R, Delap M. Topical tacrolimus for facial psoriasis. Br J Dermatol 2003;149:419-20.

  84. Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial soriasis. Eur J Dermatol 2003;13:471-3.

  85. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51:723-30.

  86. Lebwohl MG, Tan MH, Meador SL, Singer G. Limited application of fluticasone ropionate ointment, 0.005% patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001;44:77–82.



>Revistas >Medicina Cutánea Ibero-Latino-Americana >Año2005, No. 4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019